In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Behind the DES Debate: A New Model for Device Development?

Executive Summary

The drug-eluting stent is the rare cardiovascular device that has seen large companies dominate not just sales and distribution channels, but product development as well. But this big company dominance/small company exclusion in DES seems to be reversing itself, at least in part, if vibes from this year's PCR are to be trusted. Over the past half year or so, a series of newly released and much debated clinical studies, including BASKET-LATE and the Swedish DES registry SCAAR, have focused attention on DES safety issues, highlighting a small but meaningful risk of late-stent thrombosis, while the COURAGE trial has even pointed to efficacy concerns of percutaneous interventions, generally speaking. And that's opened the door to dozens of small and mid-sized companies that suddenly find themselves in the enviable position of seeing market and clinical pressures accelerating demand for quick development of their technologies.
Advertisement

Related Content

Top Device Stories of the Decade
VCs Keep Capital Flowing To Stent Start-Ups
B. Braun's Bet on Balloons
TCT Debates Cardiology's "Climate of Calamity"
ESC Highlights: DES Debate Continues, Hybrid-Imaging Hot Ticket
EuroPCR Highlights: CoStar Fizzles, Xience Sizzles
Profiles of COURAGE: Another Speed Bump for Stents or Flawed Trial?
From Academia to Commercial Success: An Interview with Frank Litvack, MD
Turning Around Medtronic Vascular
OrbusNeich: Tissue Engineering Meets Coronary Stents

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002955

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel